

500 Chipeta Way, Salt Lake City, Utah 84108-1221

phone: 801-583-2787, toll free: 800-522-2787

Jonathan R. Genzen, MD, PhD, Chief Medical Officer

Patient Age/Sex: 45 years Male

Specimen Collected: 13-Jun-23 11:13

C5 Inhibitors Drug Monitoring Panel | Received: 13-Jun-23 11:18 Report/Verified: 13-Jun-23 11:18

Procedure	Result	Units	Reference Interval
C5 Inhibitors Drug Monitoring Panel	See Note ⁱ¹		

C5 Inhibitors Drug Monitoring Panel | Received: 13-Jun-23 11:18 Report/Verified: 13-Jun-23 11:33

Procedure	Result	Units	Reference Interval
Complement C5, Concentration	10 ^{f1}	mg/dL	[7-20]
Alternative Complement Pathway Activity	30 ^L ^{f2} ⁱ²	% Normal	[>=31]
Complement Activity, Total Turbidimetric	75.0 ^{f3} ⁱ³	U/mL	[38.7-89.9]
Complement C5, Functional	25.0 ^{f4} ⁱ⁴	U/mL	[>=23.0]

Result Footnote

f1: Complement C5, Concentration

Normal C5 concentration suggests sufficient C5 protein level. In rare cases, C5 complement protein can be nonfunctional but present at normal levels. If clinically indicated, testing for C5 functional activity is suggested (test code 3005960).

f2: Alternative Complement Pathway Activity

Absent or low complement alternative pathway functional (AH50) activity indicates inherited or acquired deficiencies in complement components, or a secondary consumption process or response to therapy. Low or absent AH50 activity with normal total complement functional (CH50, test code 3002575) activity suggests defects in alternate complement pathway. Low CH50 and AH50 results suggest defects in late complement components C3-C9 or a secondary consumption of complements. Low or absent AH50 activity due to abnormal control of the complement alternative pathway may occur in kidney diseases such as atypical hemolytic uremic syndrome, C3 glomerulonephritis, and dense-deposit disease, as well as in atypical postinfectious glomerulonephritis. If low AH50 value is unexpected or does not correlate with the patient's clinical condition, repeat analysis with a fresh frozen serum specimen is suggested for verification.

f3: Complement Activity, Total Turbidimetric

Normal activity in total complement functional assay (CH50) suggests normal presence and function of complement components, C1-C9. However, normal CH50 result can also occur in the presence of low levels of complement components due to excess presence of complement proteins in human serum. If clinically indicated, measurement of individual complement components is recommended. Normal CH50 result with low complement alternate pathway functional (AH50, test code 2005373) activity suggests defects in the alternate pathway.

f4: Complement C5, Functional

Low-normal C5 functional results should be re-tested using a new specimen. If repeat results are still low-normal the test sample likely has normal C5 functional activity. Normal C5 functional activity suggests sufficient C5 protein levels and functional activity.

Test Information

i1: C5 Inhibitors Drug Monitoring Pan Interp

INTERPRETIVE INFORMATION: C5 Inhibitors Drug Monitoring Panel

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-164-900179

Report Request ID: 17765794

Printed: 22-Jun-23 11:59

Page 1 of 2

Test Information

i1: C5 Inhibitors Drug Monitoring Pan Interp
Patients treated with C5 inhibitors may show decreased/absent activity in total complement functional assay (CH50), alternative pathway functional assay (AH50), and C5 functional assay with normal or elevated C5 protein concentrations. Normal CH50, AH50, or C5 functional activity with normal or elevated C5 protein concentrations indicate inadequate complement blockage. Serial measurements are recommended when monitoring treatment efficacy. Decreases in both C5 concentration and C5 functional activity suggests a secondary consumption process or C5 deficiency. Repeat testing using a new specimen is suggested if in vitro complement activation and consumption of components due to conditions of collection, transport, and/or handling is suspected.

i2: Alternative Complement Pathway Activity

i3: Complement Activity, Total Turbidimetric

REFERENCE INTERVAL: Complement Activity Total, (CH50)

38.6 U/mL or lessLow

38.7-89.9 U/mLNormal

90.0 U/mL or greaterHigh

i4: Complement C5, Functional

REFERENCE INTERVAL: Complement C5, Functional

Low: Less than 23 U/mL

Low-Normal: Greater than or equal to 23-28.3 U/mL

Normal: Greater than 28.3 U/mL

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-164-900179

Report Request ID: 17765794

Printed: 22-Jun-23 11:59